NewAmsterdam Pharma pany N.V.(NAMS) - 2024 Q2 - Quarterly Results

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results -- Reported positive topline data from pivotal Phase 3 BROOKLYN trial evaluating obicetrapib in patients with HeFH; achieved primary endpoint of LS mean reduction in LDL-C versus placebo, as well as statistically significant reductions in other biomarkers, with safety results comparable to placebo – -- Extended US IP protection into 2043 with a new composition of matter patent -- -- On-track to report topline data fro ...